MDT

94.83

-0.27%↓

VEEV

293.46

-1.25%↓

A

138.64

+8.17%↑

HQY

90.28

-4.74%↓

PHR.US

22.45

-4.59%↓

MDT

94.83

-0.27%↓

VEEV

293.46

-1.25%↓

A

138.64

+8.17%↑

HQY

90.28

-4.74%↓

PHR.US

22.45

-4.59%↓

MDT

94.83

-0.27%↓

VEEV

293.46

-1.25%↓

A

138.64

+8.17%↑

HQY

90.28

-4.74%↓

PHR.US

22.45

-4.59%↓

MDT

94.83

-0.27%↓

VEEV

293.46

-1.25%↓

A

138.64

+8.17%↑

HQY

90.28

-4.74%↓

PHR.US

22.45

-4.59%↓

MDT

94.83

-0.27%↓

VEEV

293.46

-1.25%↓

A

138.64

+8.17%↑

HQY

90.28

-4.74%↓

PHR.US

22.45

-4.59%↓

Search

Akebia Therapeutics Inc

Geschlossen

BrancheGesundheitswesen

2.68 -1.47

Übersicht

Veränderung der Aktienkurses

24h

Aktuell

Min

2.67

Max

2.73

Schlüsselkennzahlen

By Trading Economics

Einkommen

-5.9M

247K

Verkäufe

5.1M

62M

Gewinnspanne

0.395

Angestellte

181

EBITDA

-6.1M

7.4M

Empfehlungen

By TipRanks

Empfehlungen

Starkes Kaufsignal

12-Monats-Prognose

+156.41% upside

Dividenden

By Dow Jones

Nächstes Ergebnis

6. Nov. 2025

Marktstatistiken

By TradingEconomics

Marktkapitalisierung

-162M

726M

Vorheriger Eröffnungskurs

4.15

Vorheriger Schlusskurs

2.68

Nachrichtenstimmung

By Acuity

94%

6%

356 / 371 Ranking in Healthcare

Technischer Score

By Trading Central

Vertrauen

Strong Bullish Evidence

Akebia Therapeutics Inc Chart

Vergangene Performances sind kein verlässlicher Indikator für zukünftige Ergebnisse.

Ähnliche Nachrichten

30. Sept. 2025, 23:56 UTC

Akquisitionen, Fusionen, Übernahmen

Eagers Automotive Enters Canada Via A$1 Billion Investment in CanadaOne Auto

30. Sept. 2025, 23:43 UTC

Heiße Aktien

Stocks to Watch: GEO Group, Lithium Americas, Nike

30. Sept. 2025, 23:12 UTC

Ergebnisse

Nike 1Q Sales Rise But Warns of Continued Weakness in China -- 2nd Update

30. Sept. 2025, 22:48 UTC

Akquisitionen, Fusionen, Übernahmen

Lifeway Foods, Danone Agree to Stay Litigation -- Update

30. Sept. 2025, 22:01 UTC

Akquisitionen, Fusionen, Übernahmen

Lifeway Foods, Danone Agree to Stay Litigation

30. Sept. 2025, 21:17 UTC

Ergebnisse

Nike 1Q Sales Rise as Turnaround Progresses -- Update

30. Sept. 2025, 20:47 UTC

Ergebnisse

Nike 1Q Sales Rise as Turnaround Progresses

30. Sept. 2025, 23:45 UTC

Market Talk

Nikkei May Trade in a Range Amid Uncertainty Over U.S. Govt Shutdown -- Market Talk

30. Sept. 2025, 23:45 UTC

Market Talk

Gold Edges Higher Amid Ongoing U.S. Government Shutdown Risks -- Market Talk

30. Sept. 2025, 23:26 UTC

Akquisitionen, Fusionen, Übernahmen

Eagers Automotive to Issue Shares at A$21.00 Each Via Entitlement Offer

30. Sept. 2025, 23:26 UTC

Akquisitionen, Fusionen, Übernahmen

Eagers Automotive to Launch Partly Underwritten A$452 Million Entitlement Offer

30. Sept. 2025, 23:25 UTC

Akquisitionen, Fusionen, Übernahmen

Eagers Automotive Says Equity Raising Includes A$50 Million Placement to Mitsubishi

30. Sept. 2025, 23:24 UTC

Akquisitionen, Fusionen, Übernahmen

Eagers Automotive Says Transaction With Mitsubishi Corp Worth A$70 Million

30. Sept. 2025, 23:24 UTC

Akquisitionen, Fusionen, Übernahmen

Eagers Automotive Says Mitsubishi Corp to Acquire 20% of easyauto123

30. Sept. 2025, 22:54 UTC

Market Talk

Timing of CSL's Change of CFO Queried by Bull -- Market Talk

30. Sept. 2025, 22:38 UTC

Ergebnisse

Nike Tops Earnings Estimates and Posts Surprise Revenue Increase. The Stock Inches Higher. -- Barrons.com

30. Sept. 2025, 22:32 UTC

Market Talk

Global Forex and Fixed Income Roundup: Market Talk

30. Sept. 2025, 22:32 UTC

Market Talk

Commonwealth Bank Pushes Out Next RBA Rate Cut to February -- Market Talk

30. Sept. 2025, 22:03 UTC

Akquisitionen, Fusionen, Übernahmen

Berkshire's Potential Deal for Occidental Chemical Business Would Be a Win for Buffett -- Barrons.com

30. Sept. 2025, 21:32 UTC

Akquisitionen, Fusionen, Übernahmen

Berkshire's Potential Deal for Occidental Chemical Business Would Be a Win for Buffett -- Barrons.com

30. Sept. 2025, 21:02 UTC

Ergebnisse

Nike Tops Earnings Estimates and Posts Surprise Revenue Increase. The Stock Inches Higher. -- Barrons.com

30. Sept. 2025, 20:50 UTC

Market Talk

Health Care Roundup: Market Talk

30. Sept. 2025, 20:50 UTC

Market Talk
Ergebnisse

Auto & Transport Roundup: Market Talk

30. Sept. 2025, 20:50 UTC

Market Talk

Basic Materials Roundup: Market Talk

30. Sept. 2025, 20:28 UTC

Ergebnisse

Nike Tops Earnings Estimates and Posts Surprise Revenue Increase. The Stock Rises. -- Barrons.com

30. Sept. 2025, 20:22 UTC

Ergebnisse

Nike 1Q North America Revenue $5.02B >NKE

30. Sept. 2025, 20:22 UTC

Ergebnisse

Nike 1Q Asia Pacific & Latin America Revenue $1.49B >NKE

30. Sept. 2025, 20:22 UTC

Ergebnisse

Nike 1Q Europe, Middle East & Africa Revenue $3.33B >NKE

30. Sept. 2025, 20:22 UTC

Ergebnisse

Nike 1Q Greater China Revenue $1.51B >NKE

30. Sept. 2025, 20:19 UTC

Ergebnisse

Nike Cash and Equivalents and Short-Term Investments Were $8.6 B as of Aug 31 >NKE

Peer-Vergleich

Kursveränderung

Akebia Therapeutics Inc Prognose

Kursziel

By TipRanks

156.41% Vorteil

12-Monats-Prognose

Durchschnitt 7 USD  156.41%

Hoch 8 USD

Tief 6 USD

Basierend auf 3 Wall-Street-Analysten, die in den letzten 3 Monaten 12-Monats-Kursziele für Akebia Therapeutics Inc – Dist angeboten haben.

Rating-Konsens

By TipRanks

Starkes Kaufsignal

3 ratings

3

Buy

0

Halten

0

Sell

Technischer Score

By Trading Central

2.345 / N/AUnterstützung & Widerstand

Kurzfristig

Strong Bullish Evidence

Mittelfristig

Strong Bullish Evidence

Langfristig

Bullish Evidence

Stimmung

By Acuity

356 / 371 Ranking in Gesundheitswesen

Nachrichtenstimmung

Sehr starke bärische Evidenz

Volatilität

Unterdurchschnittlich

Nachrichtenvolumen (RCV)

Unterdurchschnittlich

Finanzen

Vertriebs- und Verwaltungskosten

Betriebsaufwand

Gewinn vor Steuern

Verkäufe

Umsatzkosten

Bruttogewinn aus dem Verkauf

Zinsaufwand für Schulden

EBITDA

Betriebsergebnis

$

Über Akebia Therapeutics Inc

Akebia Therapeutics, Inc., a biopharmaceutical company, focuses on the development and commercialization of therapeutics for patients with kidney diseases. The company's lead product investigational product candidate is Vafseo (vadadustat), an oral hypoxia-inducible factor prolyl hydroxylase, which is in Phase III development for the treatment of anemia due to chronic kidney disease (CKD) in dialysis-dependent and non-dialysis dependent patients. It offers Auryxia, a ferric citrate that is used to control the serum phosphorus levels in adult patients with DD-CKD on dialysis; and the treatment of iron deficiency anemia in adult patients with CKD not on dialysis. The company's product pipeline includes AKB-9090, a drug targeting critical-care indications; and AKB-10108, a drug targeting conditions related to premature birth. It has collaboration agreements with Mitsubishi Tanabe Pharma Corporation for the development and commercialization of vadadustat in Japan and other Asian countries, as well as research and license agreement with Janssen Pharmaceutica NV for the development and commercialization of hypoxia-inducible factor prolyl hydroxylase targeted compounds worldwide. Akebia Therapeutics, Inc. was incorporated in 2007 and is headquartered in Cambridge, Massachusetts.
help-icon Live chat